SUNLENCA's Patent Extension Gets FDA Timestamp Approval
Published Date: 5/12/2025
Notice
Summary
The FDA has officially set the review period for SUNLENCA, a human drug product, so its patent can be extended. This means the company behind SUNLENCA gets more time to protect their invention, helping them keep making and selling the drug without competition for longer. If you’re in the pharma world, watch for this patent extension—it affects when generics can enter the market and could impact drug prices and availability.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
SUNLENCA patent extension delays generics
The FDA has determined the regulatory review period for the drug SUNLENCA, which allows the drugmaker to apply for and receive a patent extension. You (if you take SUNLENCA or pay for prescriptions) could see generic versions enter the market later, which may keep prices higher or affect availability.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in